#16
|
||||
|
||||
Autoimmune Thrombocytopenia Complicated by EDTA- and/or Citrate-Dependent Pseudothrombocytopenia
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#17
|
||||
|
||||
Ïîäñ÷åò òðîìáîöèòîâ â êðîâè ñ ÝÄÒÀ èëè öèòðàòîì - äåéñòâèòåëüíî ëè åñëè öèòðàòíûå òðîìáîöèòû óìíîæèòü íà 1.1, òî áóäåò ñòîëüêî æå, êàê è â êðîâè ñ ÝÄÒÀ? Îêàçûâàåòñÿ - íåò: äàæå ïîñëå ó÷åòà 10% ðàçâåäåíèÿ ÷èñëî òðîìáîöèòîâ â öèòðàòå â ñðåäíåì íà 12-13% íèæå, ÷åì â êðîâè ñ ÝÄÒÀ, äåòàëè è òîíêîñòè äîñòóïíû çíàòîêàì ìåäèöèíñêîãî ôðàíöóçñêîãî, òê ïîëíûé òåêñò òîëüêî íà ýòîì ÿçûêå:
Ann Biol Clin (Paris). 2011 Jul-Aug;69(4):453-8. [Automatic platelets numbering with citrate as anticoagulant: is the result valid?]. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] êàðòèíêè [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#18
|
||||
|
||||
Pseudothrombocytopenia due to Platelet Clumping: A Case Report and Brief Review of the Literature
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#19
|
||||
|
||||
Pseudothrombocytopenia with multiple anticoagulant sample collection tubes
PLT measurement was repeated in various anticoagulant [sodium citrate, lithium heparin, disodium oxalate, hirudin, and magnesium sulfate (Mg-sulfate)] sample collection tubes and all of them showed thrombocytopenia except with Mg-sulfate. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#20
|
||||
|
||||
Îïèñàíèå êëèíè÷åñêîãî ñëó÷àÿ ïñåâäîòðîìáîöèòîïåíèè â ðóíåòå:
Ñ.Â. Êóëåøîâà, À.À. Àëòàåâà, Å.À.Êóçíåöîâà Êëèíè÷åñêèå ñëó÷àè ëîæíîé è èñòèííîé òðîìáîöèòîïåíèè â àìáóëàòîðíîé ïðàêòèêå. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#21
|
||||
|
||||
Estimation of Platelet Counts and Other Hematological Parameters in Pseudothrombocytopenia Using Alternative Anticoagulant: Magnesium Sulfate.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#22
|
||||
|
||||
Êðîìå, ÝÄÒÀ-çàâèñèìîé, âñå ÷àùå ìîæíî çàìåòèòü öèòðàò/ãåïàðèí-çàâèñèìóþ ïñåâäîòðîìáîöèòîïåíèþ â ëàá. ïðàêòèêå, íåðåäêî ïñåâäîòðîìáîöèòîïåíèè ñóïóòñòâóåò è èñòèííàÿ, ïîðîé ýòî íå ïðîñòî ëàá. ôåíîìåí, à ñîïóòñòâ. ïðîÿâëåíèå êàêîãî-òî çàáîëåâàíèÿ, ïîäðîáíåå:
355 specimens with pseudo-thrombocytopenia (PTCP) were evaluated via epidemiology, identification, remedies, and platelet (PLT) count. Data showed that anticoagulants such as citrate and/or heparin-dependent PTCP (16.0%) became increasingly common, whereas ethylenediaminetetraacetic acid (EDTA)-induced PTCP (49.1%) remained the most frequent. We note that that nearly half of the patients with PTCP had veritable decreased PLT counts, even after PLT levels had been corrected. Our findings suggest that there were seasonal changes in patients with PTCP: PLT levels were higher in spring, compared with other seasons, with winter levels being the lowest. There were higher risks of PTCP for individuals with malignant neoplasms, liver diseases, infection, and hematologic disease, compared with other conditions. --- Lab Med. 2018 Mar 21;49(2):130-133. Spurious Thrombocytopenia in Automated Platelet Count. Zhang L è ñîàâò.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
|
#23
|
||||
|
||||
Platelet Satellitism [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#24
|
||||
|
||||
Áîëåå ðåäêèé ñëó÷àé òðîìáîöèòàðíîãî ñàòåëëèòèçìà - òðîìáîöèòû âîêðóã îïóõîëåâûõ ëèìôîöèòîâ:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#25
|
||||
|
||||
Journal of Laboratory Medicine | Volume 44: Issue 5
Pseudo-thrombocytopenia (PTCP). A challenge in the daily laboratory routine? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#26
|
||||
|
||||
Pseudothrombocytopenia—A Review on Causes, Occurrence and Clinical Implications 2021
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#27
|
||||
|
||||
COVID-19-associated pseudothrombocytopenia
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#28
|
||||
|
||||
Îïèñàíèå ñëó÷àÿ ïñåâäî-òðîìáîöèòîïåíèè ó çäîðîâîé äåâî÷êè 5 ëåò ñ êàðòèíêàìè - îáðàùàåò íà ñåáÿ âíèìàíèå, ÷òî èñêëþ÷åíèå ïñåâäî-ÒÏ òðåáóåò ïîâòîðíîãî êðîâåçàáîðà ñ öèòðàòîì, ïîâòîð ñ ÝÄÒÀ - äëÿ íàãëÿäíîñòè; íî âûïîëíåíèå àíàëèçà ÷åðåç 5 ìèíóò, à íå ïîë÷àñà-÷àñ ïîêàçûâàåò, ÷òî ÝÄÒÀ çàâèñèìîå ñëèïàíèå òðîìáîöèòîâ â ïðîáèðêå çàâèñèò îò òåìïåðàòóðû è âðåìåíè (åñëè áû ïåðâûé àíàëèç áûë ñäåëàí òàêæå áûñòðî,òî íèêàêîé ïñåâäî-ÒÏ áû íå áûëî - òðîìáîöèòû ïîâòîðíî 194, õîòÿ è íèæå, ÷åì ñ öèòðàòîì 309, íåñìîòðÿ íà 10% äèëþöèîííûé ýôôåêò öèòðàòà). Ïîêàçàíû ñëèïøèåñÿ òðîìáîöèòû â ìàçêå è "çóá÷àòàÿ ïèëà" èç ìèêðî-àãðåãàòîâ íà òðîìáîöèòàðíîé ãèñòîãðàììå[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#29
|
||||
|
||||
åùå ñòàòüÿ íà ðóññêîì 2023 ãîäà ñ îïèñàíèåì êëèíè÷åñêîãî ñëó÷àÿ ñ äëèòåëüíûì àíàìíåçîì:
"Ôåíîìåí ëîæíîé òðîìáîöèòîïåíèè. Àëãîðèòì ðåøåíèÿ äèàãíîñòè÷åñêîé ïðîáëåìû è îïèñàíèå êëèíè÷åñêîãî ñëó÷àÿ" [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |